Regencell Bioscience Holdings (RGC) Accounts Payables (2021 - 2022)
Regencell Bioscience Holdings (RGC) reported Accounts Payables of $15650.0 for Q2 2022, down 81.1% on a YoY basis from $82812.0 in Q2 2021, and down 81.1% quarter-over-quarter from $82812.0 in Q2 2021.
Regencell Bioscience Holdings (RGC) Accounts Payables (2021 - 2022) Analysis & Trends
Regencell Bioscience Holdings has reported Accounts Payables for 2 years, with the latest figure at $15650.0 in Q2 2022.
- For the quarter ending Q2 2022, Accounts Payables fell 81.1% year-over-year to $15650.0; the trailing twelve-month figure through Jun 2022 stood at $15650.0 (down 81.1% YoY), and the FY2022 full-year result was $15650.0, down 81.1% from the prior year.
- Accounts Payables for Q2 2022 stood at $15650.0, down from $82812.0 in the prior quarter.
- The five-year high for Accounts Payables was $82812.0 in Q2 2021, with the low at $15650.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 2.60 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 507.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 498.30 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 48.78 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 773.00 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 372.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 102.36 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 306.87 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 45.88 Mn |
| 10 | Regencell Bioscience Holdings | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 15,650.00 |
| Jun 30, 2021 | 82,812.00 |